KPV

Approval status

Not approved as a medicine in any country. FDA had listed it among compounding substances that may pose significant safety risks, citing no human exposure data. It came off that list in April 2026 after its nomination was withdrawn, but it is still not a substance pharmacies may compound with. In July 2026 FDA staff reviewed it for wound healing and inflammatory conditions and advised against allowing it; news reports say FDA's advisory panel narrowly voted to recommend it.^1456711

What it’s used or studied for

• Animal & lab only

  Inflammatory bowel disease: in mice with chemically induced colitis, KPV given by mouth, alone or in nanoparticles, reduced gut inflammation.⁸⁹

• Animal & lab only

  Skin wounds and skin inflammation: rodent and lab studies suggest anti-inflammatory and wound-healing effects. Researchers say human trials are still needed.¹³

• Animal & lab only

  Inflammation elsewhere in the body: in mice, KPV reduced inflammation of the abdominal lining, apparently by blocking the effects of interleukin-1.¹⁰

Each label shows how strong the evidence is: an approved use, human studies, animal or lab studies only, or a popular claim with no published studies. Being studied is not the same as being proven safe or effective.

Side effects

There are no published human safety data. FDA found no human exposure data, no adverse event reports and no animal toxicity studies for KPV.¹

Cautions

• FDA says the safety of KPV in people is unknown, including whether it triggers immune reactions or clumps (aggregates).¹